ライフサイエンスコーパス: treatment efficacy

1 development, differentiation, migration, and treatment efficacy.

2 to accurate molecular sub-classification and treatment efficacy.

3 ing cancer drugs with significantly improved treatment efficacy.

4 utcome and as a possible approach to monitor treatment efficacy.

5 C, optimized=0.25 Tg C) to achieve the same treatment efficacy.

6 oncentration, which is associated with lower treatment efficacy.

7 ancer drugs is important for optimization of treatment efficacy.

8 t some host-related factors may have limited treatment efficacy.

9 CI]: 1.76 to 3.69) in overall and short-term treatment efficacy.

10 specific clonotypes as a surrogate marker of treatment efficacy.

11 athogenesis, and may help in predicting BVMD treatment efficacy.

12 ET measurements, allowing early detection of treatment efficacy.

13 t radiation energy within tumors and promote treatment efficacy.

14 lecular characteristics, which could improve treatment efficacy.

15 elopment and is often used as a landmark for treatment efficacy.

16 ints for determining patient eligibility and treatment efficacy.

17 sive evidence showed that HIV status altered treatment efficacy.

18 quired to protect existing drugs and enhance treatment efficacy.

19 of brain tumor therapeutics to improve their treatment efficacy.

20 infiltrates in tumors is crucial to improve treatment efficacy.

21 ents of the down-staging protocol as well as treatment efficacy.

22 nd (15)O-H(2)O PET have potential to predict treatment efficacy.

23 a novel biomarker for clinical evaluation of treatment efficacy.

24 should not be considered as a measure of the treatment efficacy.

25 ces to ensure prompt diagnosis and to assess treatment efficacy.

26 serve as an indirect functional indicator of treatment efficacy.

27 provide additional drug targets to increase treatment efficacy.

28 tics, recurrence monitoring, and therapeutic treatment efficacy.

29 mor Th1 balance can differentially shape the treatment efficacy.

30 compounds, assessment of disease status, and treatment efficacy.

31 tiinflammatory properties, thereby improving treatment efficacy.

32 of the immunologic changes that can lead to treatment efficacy.

33 le on long-term outcomes, comorbidities, and treatment efficacy.

34 ures for diagnosis, resistance patterns, and treatment efficacy.

35 lciparum in Southeast Asia threatens malaria treatment efficacy.

36 to other chemotherapeutic drugs and restore treatment efficacy.

37 ir levels in tissue are inversely related to treatment efficacy.

38 intrinsic mechanisms to profoundly influence treatment efficacy.

39 f Chagas disease for diagnosis and to assess treatment efficacy.

40 components should be targeted for optimal MM treatment efficacy.

41 is (days 7, 21, and 35) was used to evaluate treatment efficacy.

42 ine the dose effect on tumor vasculature and treatment efficacy.

43 ss conclusions were robust to uncertainty in treatment efficacy.

44 xplore the mechanisms that influence overall treatment efficacy.

45 carriers who did not, without differences in treatment efficacy.

46 ith a small-molecule inhibitor increases RFB-treatment efficacy.

47 ole of autocrine VEGF signaling on sorafenib treatment efficacy.

48 hronic pain disorders, rumination can impede treatment efficacy.

49 andomized participants needed to demonstrate treatment efficacy.

50 e used for routine monitoring and evaluating treatment efficacy.

51 target site accumulation, drug release, and treatment efficacy.

52 tm1 p.R69C mouse in hopes of finding greater treatment efficacy.

53 ed how renal neural network anatomy affected treatment efficacy.

54 event (pharyngitis) and 1 because of lack of treatment efficacy.

55 in ASD could be an informative biomarker of treatment efficacy.

56 radients occur, with the potential to impact treatment efficacy.

57 rug resistance, and real-time readout on the treatment efficacy.

58 iretroviral therapy (ART) is used to monitor treatment efficacy.

59 e of this system can also be used to monitor treatment efficacy.

60 ncer drugs to the mitochondria might improve treatment efficacy.

61 ffector cells including NK cells may improve treatment efficacy.

62 treated with adalimumab is shown to diminish treatment efficacy.

63 g of circulating estrogens may be related to treatment efficacy.

64 differences in neoangiogenesis that predict treatment efficacy.

65 of rheumatoid arthritis and in monitoring of treatment efficacy.

66 n for both diagnosing disease and monitoring treatment efficacy.

67 -stimulating cytokines are required for full treatment efficacy.

68 hrough inhibitory immunoglobulins that limit treatment efficacy.

69 s of therapies to neoplastic cells and blunt treatment efficacy.

70 te preclinical models for in vivo testing of treatment efficacy.

71 t on tumor growth were analyzed to determine treatment efficacy.

72 g demonstrated for assessment of disease and treatment efficacy.

73 assays but that may significantly influence treatment efficacy.

74 t antibody interactions with its targets and treatment efficacy.

75 (ii) HAP-IR scheduling may impact treatment efficacy.

76 infected hosts could be used to demonstrate treatment efficacy.

77 aging features on diffusion MR and anti-VEGF treatment efficacy.

78 ve demonstrated significant major outpatient treatment efficacy.

79 ([(225)Ac]hu11B6-IgG(1)) has shown promising treatment efficacy.

80 tious enteric virus indicators of wastewater treatment efficacy.

81 critical closing pressure; Pcrit) and assess treatment efficacy.

82 al effect of RTX decreases, which argues for treatment efficacy.

83 bial taxa associated with disease course and treatment efficacy.

84 ssels contribute significantly to suboptimal treatment efficacy.

85 VOC-based diagnosis of tumor progression and treatment efficacy.

86 icant determinants of (greater-than-average) treatment efficacy.

87 a tumor's glycobiological state will improve treatment efficacy.

88 armacogenomics of buprenorphine response and treatment efficacy.

89 host response, with a potential influence on treatment efficacy.

90 drug to the combination is likely to improve treatment efficacy.

91 total disease burden or surrogates to assess treatment efficacy.

92 biomarker candidate to predict prognosis and treatment efficacy.

93 D) are not well understood yet important for treatment efficacy.

94 gnition remains essential to afford the best treatment efficacy.

95 rubicin and anti-221, for improving leukemia treatment efficacy.

96 switch does not support the view of a longer treatment efficacy.

97 er multiple or rotating regimens to maintain treatment efficacies.

98 rements for clinical trials for hypothesised treatment efficacies.

99 nitalium) AND (azithromycin OR zithromax OR [treatment efficacy]).

100 d overall were: physical side effects (83%); treatment efficacy (79%), new treatment drugs in develop

101 We compared treatment efficacy according to blood eosinophil percent

102 se, the quality of health-care delivery, and treatment efficacy across various disease settings.

103 nsferase and DNA hypermethylation, has shown treatment efficacy against multiple malignancies by supp

104 However, treatment efficacy against two isolates of P. digitatum

105 of which contribute greatly to the optimized treatment efficacy along with minimized side effects.

106 Main outcome measures consisted of treatment efficacy and adverse events.

107 is an urgent need for biomarkers to monitor treatment efficacy and anticipate outcome in patients wi

108 erm starvation or fasting can augment cancer treatment efficacy and can be effective in delaying canc

109 eview the limited data available surrounding treatment efficacy and clinical outcomes in patients who

110 To determine true treatment efficacy and define the most appropriate retre

111 stic and prognostic information, quantifying treatment efficacy and designing better therapeutics.

112 We describe models of mechanisms of treatment efficacy and discuss recent treatment-specific

113 treatment with methylphenidate may decrease treatment efficacy and exacerbate symptoms while not und

114 ients undergo imaging surveillance to assess treatment efficacy and identify potential sites of progr

115 Further study of treatment efficacy and its underlying neurocognitive mec

116 eing intensively investigated to improve the treatment efficacy and life qualities for diabetic patie

117 latin does not seem to substantially improve treatment efficacy and may increase toxicity and mortali

118 ce of invasive cancer, but few data exist on treatment efficacy and natural regression without treatm

119 ted strategies could be exploited to improve treatment efficacy and outcome, contain drug-resistant s

120 this knowledge can be exploited to increase treatment efficacy and patient survival.

121 ressure is known to correlate with decreased treatment efficacy and potentially with tumour aggressiv

122 with wider range of dose rate for improving treatment efficacy and reduction of side effects, a bett

123 a consistent finding within MDD; can predict treatment efficacy and reverses following successful tre

124 istry of mCRC patients aiming to compare the treatment efficacy and safety according to the age categ

125 To achieve desired treatment efficacy and safety profiles, drug release kin

126 Chemoradiation-resistant cancers limit treatment efficacy and safety.

127 Doxil-induced IR without adversely affecting treatment efficacy and safety.

128 MAIN OUTCOME MEASURE(S): Treatment efficacy and side effects.

129 ent genetic studies and studies of long-term treatment efficacy and side-effects have underscored the

130 Combination chemotherapy can increase treatment efficacy and suppress drug resistance.

131 CPMV also exhibited clear treatment efficacy and systemic antitumour immunity in o

132 er of these NK cells may allow monitoring of treatment efficacy and the likelihood of reservoir contr

133 ustomized amount of the drug can improve the treatment efficacy and the quality of patient life, avoi

134 eful in the study of breast cancer progress, treatment efficacy and the tailoring of individualized p

135 thyroid and hematologic monitoring to assess treatment efficacy and therapeutic toxicity in the short

136 chronic hepatitis C patients to evaluate the treatment efficacy and to identify post-treatment seroma

137 Because an optimal balance between treatment efficacy and toxicity is of utmost importance

138 lized risk-benefit assessment that evaluates treatment efficacy and toxicity.

139 between cancer cells and the TME may reduce treatment efficacy and ultimately lead to acquired drug

140 associated manifestations, natural history, treatment efficacy, and diagnostic procedures.

141 ic scarring, well-designed trials to confirm treatment efficacy, and further elucidation of molecular

142 ecalculated estimates of endpoint incidence, treatment efficacy, and statistical power using all-caus

143 predictors of treatment response, markers of treatment efficacy, and subtyping within disorders.

144 ld improve heart failure risk determination, treatment efficacy, and therapeutic discovery, and provi

145 variant which significantly improved in vivo treatment efficacy (animal survival increased from 20% t

146 Overall, treatment efficacy appears to be determined by the aller

147 s to assess nicotine dependence severity and treatment efficacy are essential to improve the current

148 o evaluate such designs in order to maximize treatment efficacy are time- and cost-intensive.

149 rolimus demonstrates similar overall initial treatment efficacy as prednisone.

150 an L. guyanensis infection and its effect on treatment efficacy, as well as its correlation to sympto

151 had at least one dose of study drug and post-treatment efficacy assessment.

152 herapies and prognostic information on tumor treatment efficacy, assisting in the design of individua

153 d with resistance has changed, we reassessed treatment efficacies at 3 sites in Uganda.

154 Demonstration of treatment efficacy at later time points in the postnatal

155 ccess rate (82.3% vs 67.2%; P < 0.00001) and treatment efficacy based on 1-year follow-up rate (93.1%

156 tive and clinically interpretable summary of treatment efficacy based on this curve is also proposed.

157 This finding is consistent with treatment efficacy being polygenic and suggests that sin

158 on-to-treat analysis yielded a difference in treatment efficacy between groups of -27.0% (95% CI, -31

159 s no statistically significant difference in treatment efficacy between treatment-naive patients (72%

160 asing cisplatin sensitivity and serving as a treatment efficacy biomarker.

161 Lastly, PV-267 showed treatment efficacy both in preventing experimental autoi

162 We assessed the ASSP treatment efficacy by evaluating parasite clearance half

163 romises new insights into cancer biology and treatment efficacy by integrating genomics, transcriptom

164 Cancer treatment efficacy can be significantly enhanced through

165 tor memory T cells in the blood, evidence of treatment efficacy can only be found in the allograft it

166 Treatment efficacy cannot be assessed with this measure

167 lates the distribution of subclones, loss of treatment efficacy coincides with the re-expansion of th

168 to its remarkably low side effects and high treatment efficacy compared to conventional chemotheraph

169 ersus 4.1%, P < 0.0001) without compromising treatment efficacy compared to tissue genotyping.

170 hat ctDNA analysis is better associated with treatment efficacy compared with other available methods

171 [PPV], and negative predictive value [NPV]; treatment efficacy (COPD exacerbations, all-cause mortal

172 To predict tumor treatment efficacy, data analysis was performed to ident

173 Primary outcome measure is treatment efficacy defined as the incidence of biopsy-pr

174 Treatment efficacy depends on accurate diagnosis at an e

175 Betaine treatment efficacy diminishes significantly over time du

176 Lessons learned from prior losses of treatment efficacy, drug combinations, and control strat

177 isease risk, diagnostic test properties, and treatment efficacy; exploring a more complete array of a

178 This meta-analysis estimates treatment efficacy following treatment with 1 gram of az

179 e implications for individual differences in treatment efficacy for approaches that rely on reinforce

180 vel metabolic-based strategies might enhance treatment efficacy for cancer.

181 s aimed at enhancing diagnostic accuracy and treatment efficacy for cancer.

182 ming tumor hypoxia, thus leading to an ideal treatment efficacy for complete eradication of solid tum

183 Treatment efficacy for diabetes mellitus is largely dete

184 pha2a) and ribavirin substantially increases treatment efficacy for genotype 1 chronic hepatitis C vi

185 ure clinical trials evaluating antimicrobial treatment efficacy for HABP/VABP.

186 there has been little recent improvement in treatment efficacy for major depressive disorder (MDD).

187 ient as diagnostic tools or as biomarkers of treatment efficacy for O. volvulus.

188 munotherapies have resulted in unprecedented treatment efficacy for responding patients, and have bec

189 isinin-piperaquine (DHA-PQ) showed excellent treatment efficacy for uncomplicated malaria in prior tr

190 g all minimal targets only, increasing RS TB treatment efficacy from 94% to 99% reduced TB mortality

191 Decoupling treatment efficacy from the risk of resistance can be ac

192 However, we report that treatment efficacy has a clear impact on the population

193 rgeting TAK1 as a strategy to enhance cancer treatment efficacy has been studied in several malignanc

194 was most sensitive to the magnitude of ALVD treatment efficacy; higher treatment efficacy resulted i

195 ce adverse effects and improve the infection treatment efficacy.If the first-line therapy fails a sec

196 hesized TAK1 inhibitor, greatly enhanced Dox treatment efficacy in a panel of breast cancer cell line

197 The treatment efficacy in both the subcutaneous H1975/AZDR m

198 ssociation between polymorphisms at ITPA and treatment efficacy in chronic hepatitis C mediated by re

199 core might prove useful in the assessment of treatment efficacy in clinical trials.

200 roving individual evaluation of anti-oxidant treatment efficacy in currently incurable oxidative stre

201 a major treatment goal and a key measure of treatment efficacy in decompensated heart failure.

202 ing of Siglec-7 on eosinophils might enhance treatment efficacy in eosinophil-driven disorders.

203 ement natural history studies and to monitor treatment efficacy in future clinical trials.

204 rapy and may be a useful surrogate marker of treatment efficacy in future studies.

205 hich might allow for the early prediction of treatment efficacy in HCV infection.

206 LISPOT is probably not a useful biomarker of treatment efficacy in LTBI.

207 e peritoneal cavity linearly correlated with treatment efficacy in mice (r(2)>0.8, p<0.001).

208 osis and enable more accurate assessments of treatment efficacy in migraine.

209 highly applicable and sensitive to evaluate treatment efficacy in MM.

210 be a more useful outcome measure to monitor treatment efficacy in models of Alzheimer's disease comp

211 is one of the primary reasons for suboptimal treatment efficacy in NP delivery platforms.

212 il 30, 2014, which investigated antimalarial treatment efficacy in P. vivax malaria.

213 impact of combination treatment schedules on treatment efficacy in patients with preexisting resistan

214 d by a lack of validated assays to establish treatment efficacy in pre-clinical animal models and in

215 vide a deeper understanding of apparent drug treatment efficacy in preclinical NASH studies.

216 utility of SNP data for predicting anti-TNF treatment efficacy in RA patients was performed in the c

217 of the Multifactorial Approach and Superior Treatment Efficacy in Renal Patients with the Aid of Nur

218 older patients and more accurately quantify treatment efficacy in this group.

219 for monitoring disease progression and drug treatment efficacy in vivo.

220 Given concerns that dexrazoxane may reduce treatment efficacy, induce second cancers, and thus comp

221 High treatment efficacy is achieved using dose-dense chemothe

222 but in P. vivax infections the assessment of treatment efficacy is confounded by relapse from the dor

223 Yet the treatment efficacy is diverse and the mechanism behind i

224 aluated according to aggregate measurements, treatment efficacy is generally modest and differences i

225 suffering a large-vessel occlusion, although treatment efficacy is highly time-dependent.

226 Antidepressant treatment efficacy is low, but might be improved by matc

227 However, the treatment efficacy is significantly variable in clinic o

228 One proposed method to extend treatment efficacy is to use a combination of multiple t

229 Treatment efficacy is, however, still limited, because t

230 lic AMP signaling has a key role in retinoid treatment efficacy: it enhances ATRA-induced maturation

231 s should consider that even small changes in treatment efficacy may have considerable impact on TB-re

232 The primary end point was treatment efficacy measured as the response rate in pati

233 ed in all patients who had at least one post-treatment efficacy measurement.

234 o lure bed bugs into traps for surveillance, treatment efficacy monitoring and mass trapping efforts,

235 of prostate cancer, treatment distributions, treatment efficacy, mortality, health-related quality of

236 We evaluate treatment efficacies of two different radiation regimens

237 .75 (95% CI 2545-2759) per QALY gained for a treatment efficacy of 20% and euro4243 per QALY gained f

238 cacy of 20% and euro4243 per QALY gained for treatment efficacy of 50%.

239 Finally, the treatment efficacy of all heating strategies plus additi

240 de of CXCR4 signaling significantly enhanced treatment efficacy of anti-VEGFR2 treatment in both CRC

241 2 neutralization can effectively improve the treatment efficacy of combined therapy with ADT and vacc

242 Advanced drug delivery systems (DDS) enhance treatment efficacy of different therapeutics in a dosage

243 cals and suggest concepts that might improve treatment efficacy of future drug candidates.

244 ent efforts are now focused on improving the treatment efficacy of ICB in breast cancer using new com

245 Siglec-9, such as in trials to elucidate the treatment efficacy of novel drug candidates.

246 might be a putative strategy to improve the treatment efficacy of peptide receptor chemoradionuclide

247 In vitro modeling predicts only partial treatment efficacy of targeting subclonal mutations, and

248 Treatment efficacy of the adenoviral vectors released fr

249 measurement ability in the evaluation of the treatment efficacy of the MS patients with acute attack

250 ters may affect the disposition, and thereby treatment efficacy, of anticancer drugs in human head an

251 esent at an infection site can affect either treatment efficacy or immune function.

252 no difference in terms of outcome regarding treatment efficacy or tolerability.

253 l strategy shows significant increase in the treatment efficacy over monotherapy in the experimental

254 Model outcomes were treatment efficacy, patient and payer cost, and health-r

255 informatics tasks, including prognostics and treatment efficacy predictions for better clinical decis

256 Varying treatment efficacy, price, and/or duration changed the p

257 We summarize treatment efficacy, quality of life, and adherence of th

258 Treatment efficacy quickly diminishes if not introduced

259 e benefit of available antiviral therapy, as treatment efficacy rapidly decreases following the clini

260 isms in NS5A (M28, Q30, L31, or Y93) reduced treatment efficacy; rates of SVR12 were 70% and 98% for

261 arker of artemisinin resistance) in reducing treatment efficacy remains controversial.

262 ch as mutations or neo-antigens, and maximal treatment efficacy requires that targeted alterations ar

263 (18)F-FDG revealed a treatment efficacy response only at day 10 after treatme

264 magnitude of ALVD treatment efficacy; higher treatment efficacy resulted in lower ICER.

265 g may have implications for interpreting the treatment efficacy results of in vitro experiments, in w

266 e PD-1 inhibitors could lead to increases in treatment efficacy, safety, and global access.

267 We systematically reviewed P. vivax malaria treatment efficacy studies to establish the global exten

268 p=1.7 x 10(-7), respectively) with decreased treatment efficacy (survival rates 0.38 [95% CI 0.25-0.5

269 ediated changes in cell signaling related to treatment efficacy, the delivery and histological locali

270 To assess treatment efficacy, this work paired predicted breakthro

271 nt uptake was more effective than increasing treatment efficacy to reduce HCV incidence and prevalenc

272 Treatment efficacy, tolerability, and safety profiles di

273 s a critical site to consider when assessing treatment efficacy, transmission competence and the impa

274 77)Lu-HTK03123 have the potential to improve treatment efficacy using significantly lower quantities

275 differences with respect to drug delivery or treatment efficacy using vismodegib.

276 Mean duration of treatment efficacy was 127 days (SD 37) with a 5% physic

277 Treatment efficacy was assessed by baseline risk for CV

278 The treatment efficacy was assessed by evaluating eosinophil

279 Treatment efficacy was assessed comparing LAE rates duri

280 Treatment efficacy was assessed for the entire populatio

281 Treatment efficacy was assessed on the basis of Mycobact

282 logy was more often negative (14% vs 1%) and treatment efficacy was better (51% regression after 1-ye

283 Treatment efficacy was determined by comparing the chang

284 Treatment efficacy was evaluated by using modified Respo

285 Treatment efficacy was lost after antibiotic treatments

286 Treatment efficacy was measured as microbial cure at las

287 Treatment efficacy was not affected by simultaneous trea

288 injection (PI), however the duration of this treatment efficacy was not established.

289 Treatment efficacy was not jeopardized since 3-month dis

290 Etoposide treatment efficacy was proven by ex vivo anticaspase 3 s

291 Predictability and treatment efficacy were also recorded at the end of the

292 various timepoints as an early predictor of treatment efficacy when designing phase 2 studies before

293 caffeine may be a useful adjunct to enhance treatment efficacy where indicated.

294 e to infection genotype, doctors can improve treatment efficacy while limiting costs of inappropriate

295 r radionuclide therapy (PRRT) would increase treatment efficacy while reducing systemic toxicity comp

296 d to investigate contribution of DWMR to the treatment efficacy with ADC values which were measured i

297 To determine treatment efficacy with regard to incidence and time to

298 We assessed the patients' perceptions of treatment efficacy with the Quality of Life in Essential

299 in developing future algorithms that predict treatment efficacy with V3 loop bnAbs.IMPORTANCE The eff

300 Accurate assessment of treatment efficacy would facilitate clinical trials of n